WAY-316606: Advanced Anti-Hair Loss Raw Material
Unlock superior hair growth solutions with high-purity WAY-316606, a key pharmaceutical intermediate.
Get a Quote & SampleProduct Core Value
WAY-316606
WAY-316606 is a potent sFRP-1 inhibitor (Ki=80 nM), originally developed for osteoporosis but recognized for its significant potential in combating hair loss. By antagonizing the Wnt signaling pathway, it stimulates hair follicle regeneration and growth.
- Leverage the power of WAY-316606 anti-hair loss raw material to formulate advanced hair care products.
- Benefit from the competitive WAY-316606 powder price for bulk procurement.
- Source from a reliable WAY-316606 CAS 915759-45-4 supplier for consistent quality.
- Incorporate this cutting-edge sFRP-1 inhibitor for hair growth into your next generation of treatments.
Key Advantages
High Purity & Efficacy
Achieve superior results with our pharmaceutical grade WAY-316606, boasting purity of 99%min by HPLC, ensuring maximum effectiveness in anti-hair loss formulations.
Versatile Application
This pharmaceutical intermediate is ideal for creating capsules, tablets, and pills, offering a flexible solution for various product formats in the health and beauty sectors.
Stable & Reliable
With a shelf life of 2 years and stored in cool, dry conditions, this raw powder maintains its integrity, providing a dependable ingredient for your manufacturing needs.
Key Applications
Hair Loss Treatments
Utilize the sFRP-1 inhibitor for hair growth to develop next-generation therapies targeting androgenetic alopecia and other forms of hair thinning.
Pharmaceutical Formulations
Integrate this high-quality pharmaceutical intermediate into oral dosage forms, leveraging its therapeutic potential for scalp health.
Cosmetic Ingredients
Enhance cosmetic products with the scientifically backed benefits of WAY-316606, appealing to consumers seeking advanced hair care solutions.
Research & Development
Explore the extensive benefits of this compound in R&D, furthering the understanding and application of sFRP-1 inhibition in regenerative medicine.